Form 8-K

8-K — Nuvectis Pharma, Inc.

Accession: 0001104659-26-090094

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001875558

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622125d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622125d1_ex99-1.htm)

GRAPHIC (tm2622125d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622125d1_8k.htm · Sequence: 1

false

0001875558

2026-08-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

August 4, 2026

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction

of Incorporation)

001-41264

(Commission File Number)

86-2405608

(IRS Employer Identification No.)

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

(201) 614-3150

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the

Exchange Act:

Title of Class

Trading Symbol(s)

Exchange Name

Common Stock

NVCT

Nasdaq Capital Market

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.

Results of Operations and Financial Condition.

On August 4, 2026, Nuvectis

Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June

30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.

The information, including

Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not

be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set

forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit

Number

Description

99.1

Press release issued by Nuvectis Pharma, Inc., dated August 4, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

Nuvectis Pharma, Inc.

(Registrant)

Date: August 4, 2026

By:

/s/ Ron Bentsur

Ron Bentsur

Chairman, Chief Executive Officer and President

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622125d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Nuvectis Pharma Reports Second Quarter

2026 Financial Results and Business Highlights

· Completed

in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200)

from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a

late-stage clinical development organization.

· The

Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor

for once-daily, oral administration, was approved in China in July 2026 for the treatment

of patients with PNH previously untreated with complement inhibitors.

· Completed

follow-on offering in July 2026, raising $115M in gross proceeds. Transaction anchored by

leading healthcare dedicated investors and extends cash runway into 1H 2029.

August 4,

2026, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical

company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported

its financial results for the second quarter of 2026 and provided an update on recent business progress.

Ron Bentsur,

Chairman and Chief Executive Officer of Nuvectis, commented, “The past several weeks mark a defining chapter for Nuvectis with

the in-licensing of our new lead drug candidate, ciprocopan (NXP100), a Complement Factor B Inhibitor for once-daily oral administration,

and the expansion of our oncology pipeline with the in-licensing of NXP200, an oral, brain-penetrant, paradox-breaker BRAF inhibitor.

Approximately two weeks ago, ciprocopan received its first marketing approval in China for the treatment of patients with paroxysmal

nocturnal hemoglobinuria (“PNH”) not previously treated with complement inhibitors. This approval marks the first global

approval of a once-daily, oral Complement Factor B inhibitor, bringing about a meaningful new treatment option for patients with PNH

in China, and also highlights ciprocopan’s compelling clinical profile and provides further validation of its therapeutic potential

as a treatment for a variety of complement-mediated diseases. We congratulate our partner Haisco on this significant achievement and

are excited about the opportunity to follow suit in the United States and in the other licensed territories.”

Mr. Bentsur

concluded, “As expected following an in-licensing transaction that involves a late-stage asset with a multi-billion-dollar market

potential, our main focus now is to advance ciprocopan toward a marketing application in the United States and other key territories,

with NXP200 and NXP900 driving potential longer-term upside in the oncology segment. The successful $115M follow-on offering recently

completed provides the resources necessary to advance our broad development strategy for NXP100 in PNH and other complement-mediated

diseases and execute the next stage of development across our oncology portfolio.”

Recent

Developments

· Completed

public offering in July 2026 for gross proceeds of $115 million, which includes the exercise

of the underwriters’ overallotment. Transaction was anchored by leading healthcare

investors and extends our cash runway into 1H 2029.

· Ciprocopan

(NXP100)

o In

July 2026, our partner Haisco announced marketing approval of ciprocopan in China for the

treatment of patients with PNH previously untreated with complement inhibitors. The marketing

application in China for the treatment of PNH patients previously treated with anti C5 therapy

is under review.

o U.S. regulatory efforts underway; a pre-investigation new drug

(“IND”) meeting with the Food and Drug Administration (“FDA”) followed by IND submission expected in 4Q2026.

· NXP200

o Phase

1b in China in patients with BRAF-mutated solid tumors is ongoing.

o Oral presentation of additional clinical data generated by Haisco

will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026).

o U.S. regulatory efforts underway; IND submission expected in

4Q2026.

· NXP900

o With

the shift in corporate focus towards the development of ciprocopan, the NXP900 clinical development

will now continue with the promising, higher potential impact, combination opportunities:

§ Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in

patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide

an update by the end of this year. The initiation of the combination study of NXP900 with lorlatinib (Lorbrena®) in patients with

NSCLC ALK+ who initially responded to, and later progressed on, an ALK inhibitor, is expected in 3Q2026.

§ Pancreatic cancer: Based on in-bound interest from two leading medical centers in the U.S., an investigator-sponsored trial

(IST) is planned to evaluate the combination of NXP900 plus daraxonrasib in patients with pancreatic cancer at these centers. Study initiation is

contingent on FDA approval and availability of daraxonrasib.

Second Quarter 2026 Financial

Results

Cash, and cash equivalents were $22.2 million as of June 30, 2026,

compared to $31.6 million as of December 31, 2025. In July, the Company raised $115 million in gross proceeds in a follow-on offering

anchored by leading healthcare investors.

The Company's net loss was $7.0 million for the three months ended

June 30, 2026, compared to $6.3 million for the three months ended June 30, 2025, an increase in net loss of $0.7 million. Non-cash stock-based

compensation was $1.7 million for the three months ended June 30, 2026, compared to $1.7 million for the three months ended June 30, 2025.

Research and development expenses were

$4.7 million for the three months ended June 30, 2026, compared to $3.6 million for the three months ended June 30, 2025, an increase

of $1.1 million. The increase was primarily driven by a $0.4 million increase in manufacturing costs, a $0.4 million increase in clinical

trial expenses, and a $0.3 million increase in employee compensation and benefits.

General and administrative expenses

were $2.5 million for the three months ended June 30, 2026, compared to $3.0 million for the three months ended June 30, 2025, a decrease

of $0.5 million. The decrease was primarily driven by a $0.5 million decline in professional and consulting services related to public

company expenses.

Finance income was $0.2 million for

the three months ended June 30, 2026, and $0.3 million for the three months ended June 30, 2025.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical

stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions

and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment

of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.

The company’s lead drug candidate

is ciprocopan, a Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously

untreated with complement inhibitors. In PNH and other complement-mediated diseases, ciprocopan is expected to provide a meaningful convenience

advantage as a once-daily, oral treatment option for diseases requiring lifelong treatment.

NXP200 is an oral, brain-penetrant,

paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including

central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.

NXP900 is an oral small molecule inhibitor

of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing

comprehensive shutdown of the SRC signaling pathway.

Forward Looking Statements

This press release contains “forward-looking statements”

within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other

than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained

in this press release may be identified by the use of words such as "anticipate", "believe", "contemplate",

"could", "estimate", "expect", "intend", "seek", "may", "might",

"plan", "potential", "predict", "project", "target", "aim", "should",

"will", "would", or the negative of these words or other similar expressions, although not all forward-looking statements

contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements

about the use of proceeds from the public offering and the approvability and market potential of our pipeline products. Forward looking

statements are based on Nuvectis’ current expectations, estimates, and projections and past interpretations of data and information

available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for its

pipeline products NXP100, NXP200, and NXP900, and estimates and projections regarding Nuvectis’ financial condition. The outcomes

of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other

conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to

future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions

and described more fully in the section titled "Risk Factors" in Nuvectis’ second quarter 2026 Form 10-Q and Nuvectis’

other public filings with the U.S. Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new

risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have

an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements

contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to

release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’

expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by

law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform

Act of 1995.

Company Contact

Ron Bentsur

Chairman, Chief

Executive Officer and President

rbentsur@nuvectis.com

Media Relations

Contact

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

NUVECTIS PHARMA, INC.

BALANCE SHEET

(USD in thousands,

except per share and share amounts)

June 30,

December 31,

2026

2025

Assets

CURRENT ASSETS

Cash and cash equivalents

$ 22,160

$ 31,634

Other current assets

216

TOTAL CURRENT ASSETS

22,376

31,709

TOTAL ASSETS

$ 22,376

$ 31,709

Liabilities and Shareholders’ Equity

CURRENT LIABILITIES

Accounts payable

$ 5,184

$ 6,274

Deferred fundraising receipts

1,388

—

Accrued liabilities

115

Employee compensation

and benefits

6,630

6,907

TOTAL CURRENT LIABILITIES

13,294

13,296

TOTAL LIABILITIES

13,294

13,296

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY

Common Shares, $0.00001 par value – 60,000,000 shares authorized

as of June 30, 2026, and December 31, 2025, 26,694,828, and 25,676,798 shares issued and outstanding as of June 30, 2026

and December 31, 2025, respectively

Additional paid in capital

121,839

118,100

Accumulated deficit

(112,757 )

(99,687 )

TOTAL SHAREHOLDERS’ EQUITY

9,082

18,413

TOTAL LIABILITIES AND SHAREHOLDERS’

EQUITY

$ 22,376

$ 31,709

* Represents

an amount lower than $1,000 USD.

NUVECTIS PHARMA, INC.

STATEMENT OF

OPERATIONS

(USD in thousands,

except per share and share amounts)

Three Months

Ended June 30

Six Months

Ended June 30

2026

2025

2026

2025

OPERATING EXPENSES

Research and development

$ 4,684

$ 3,613

$ 8,790

$ 7,293

General and administrative

2,513

2,982

4,667

4,870

OPERATING LOSS

(7,197 )

(6,595 )

(13,457 )

(12,163 )

Finance income

177

261

387

497

NET LOSS

$ (7,020 )

$ (6,334 )

$ (13,070 )

$ (11,666 )

TOTAL NET LOSS ATTRIBUTABLE TO COMMON

SHAREHOLDERS

$ (7,020 )

$ (6,334 )

$ (13,070 )

$ (11,666 )

BASIC AND DILUTED NET LOSS PER

COMMON SHARE OUTSTANDING

$ (0.30 )

$ (0.56 )

Basic and diluted weighted average

number of common shares outstanding

23,475,989

21,366,268

23,445,397

20,655,856

GRAPHIC

Filename: tm2622125d1_ex99-1img001.jpg · Sequence: 6

Binary file (2833 bytes)

Download tm2622125d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

001-41264

Entity Registrant Name

Nuvectis Pharma, Inc.

Entity Central Index Key

0001875558

Entity Tax Identification Number

86-2405608

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 Bridge Plaza Suite 275

Entity Address, City or Town

Fort Lee

Entity Address, State or Province

Entity Address, Postal Zip Code

07024

City Area Code

201

Local Phone Number

614-3150

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

NVCT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration